Monocytes and Tissue Factor Promote Thrombosis in a Murine Model of Oxygen Deprivation

Charles A. Lawson,* Shi Du Yan,† Shi Fang Yan,§ Hui Liao,∥ Yu Shan Zhou,¶ Joan Sobel,‡ Walter Kisiel,** David M. Stern,†† and David J. Pinsky‡‡

*Department of Anesthesiology, †Department of Pathology, ‡Department of Physiology, §Department of Surgery, and ¶Department of Medicine, Columbia University, College of Physicians and Surgeons, New York 10032; and **Department of Pathology, The University of New Mexico School of Medicine, Albuquerque, New Mexico 87131

Abstract

Clinical conditions associated with local or systemic hypoxemia can lead to prothrombotic diatheses. This study was undertaken to establish a model of whole-animal hypoxia wherein oxygen deprivation by itself would be sufficient to trigger tissue thrombosis. Furthermore, this model was used to test the hypothesis that hypoxia-induced mononuclear phagocyte (MP) recruitment and tissue factor (TF) expression may trigger the local deposition of fibrin which occurs in response to oxygen deprivation. Using an environmental chamber in which inhaled oxygen tension was lowered to 6%, hypoxic induction of thrombosis was demonstrated in murine pulmonary vasculature by 8 h based upon: (a) immunohistologic evidence of fibrin formation in hypoxic lung tissue using an antifibrin antibody, confirmed by 22.5-nm strand periodicity by electron microscopy; (b) immunoblots revealing fibrin gamma–gamma chain dimers in lungs from hypoxic but not normoxic mice or hypoxic mice treated with hirudin; (c) accelerated deposition of 125I-fibrin/fibrinogen and 111In-labeled platelets in the lung tissue of hypoxic compared with normoxic animals; (d) reduction of tissue 125I-fibrin/fibrinogen accumulation in animals which had either been treated with hirudin or depleted of platelets before hypoxic exposure. Because immunohistochemical analysis of hypoxic pulmonary tissue revealed strong MP staining for TF, confirmed by increased TF RNA in hypoxic lungs, and because 111In-labeled murine MPs accumulated in hypoxic pulmonary tissue, we evaluated whether recruited MPs might be responsible for initiation of hypoxia-induced thrombosis. This hypothesis was supported by several lines of evidence: (a) MP depletion before hypoxia reduced thrombosis, as measured by reduced 125I-fibrin/fibrinogen deposition and reduced accumulation of cross-linked fibrin by immunoblot; (b) isolated murine MPs demonstrated increased TF immunostaining when exposed to hypoxia; and (c) administration of an anti–rabbit TF antibody that cross-reacts with murine TF decreased 125I-fibrin/fibrinogen accumulation and cross-linked fibrin accumulation in response to hypoxia in vivo. In summary, these studies using a novel in vivo model suggest that MP accumulation and TF expression may promote hypoxia-induced thrombosis. (J. Clin. Invest. 1997. 99:1729–1738.) Key words: fibrin • tissue factor • monocyte • hypoxia • coagulation

Introduction

Venous thromboembolism is a major cause of morbidity and mortality, and is associated with major trauma, orthopedic surgery, and limb immobilization (1, 2). Lower-extremity venous thrombosis may result in chronic venous insufficiency and is also the precursor of pulmonary embolism that results in 50,000 to 100,000 deaths per year (3). Stasis of blood contributes to thrombi under these conditions, and thrombus formation has been localized to the parietal aspect of venous valve cusps where depositions of platelets, leukocytes, and fibrin–like material have been described (4). Severe hypoxemia has been recorded at this same anatomic site within 2 h in a canine limb immobilization model (5), and hypoxia has been implicated in the derangement of vascular endothelial anticoagulant properties (6).

Given these associations between hypoxia and thrombosis, we hypothesized that reduced oxygen states might alter the balance of anticoagulant/procoagulant mechanisms in the vasculature to favor activation of coagulation. Although most thrombosis models rely on vascular injury to provide a nidus for clotting (7–9), we have focused on how hypoxia per se may modulate properties of cells of the vascular wall to promote thrombus formation. In this study, we report an in vivo model of whole animal hypoxia, in which hypoxia promotes fibrin formation in the pulmonary vasculature. Our investigation into mechanisms by which hypoxia may trigger thrombosis was prompted by our observation that mononuclear phagocytes (MPs) accumulated in the lungs during hypoxic exposure, and were associated with the production of tissue factor (TF). Studies were undertaken to examine the possibility that MP accumulation and TF expression underlie the initiation of hypoxia-induced thrombosis. These experiments provide a model for the study of hypoxia-mediated thrombosis, and suggest that MP recruitment and local TF expression are important early events in the prothrombotic diathesis associated with oxygen deprivation.

Address correspondence to Charles A. Lawson, M.D., or David J. Pinsky, M.D., Columbia University, College of Physicians and Surgeons, MHB 4-446, 630 West 168th Street, New York, NY 10032. Phone: 212-305-2575; FAX: 212-305-2182.

Received for publication 15 February 1996 and accepted in revised form 24 January 1997.


1. Abbreviations used in this paper: MP, mononuclear phagocyte; PT, prothrombin time; TF, tissue factor.
Methods

Induction of hypoxia. In experiments approved by the Columbia University Institutional Animal Care and Use Committee, CD-1 mice (12–15 wk-old; Charles River Laboratories, Wilmington, MA) were subjected to normobaric hypoxic conditions created by the regulated addition of nitrogen to a chamber equipped with circulating fans, carbon dioxide, and ammonia elimination systems, and an on-line oxygen sensor (Horiba Ltd., Kyoto, Japan). The environment within the chamber (including temperature and humidity) was regulated by a custom-built interface (K + K Interface Inc., New York) which used an environmental control program (K + K Interface Inc.) running on an XT clone microprocessor equipped with a logic board (model Megaboard; Display Telecommunications Corp., Dallas, TX) and an analogue to digital conversion package (LabMaster Scientific Solutions Inc., Solon, OH). Mice were placed in the chamber in their usual cages and allowed free access to food and water, and the system parameters were adjusted to a final oxygen concentration of 5.5–6.5%. Mice exposed to hypoxia were observed to be tachypneic and have reduced activity, compared with normoxic counterparts. They were exposed to hypoxia for varying times, killed, and tissue was harvested for further analysis. In studies to delineate fibrin formation in lung vasculature, mice received intravenous heparin (10 U/g, resulting in the APTT > 300 s) immediately before killing to limit postmortem clotting. Normoxic control animals (not placed in the chamber) were otherwise treated in the same manner.

Immunohistology. Mice were exposed to hypoxia or normoxia for the indicated durations, tissue was harvested, cut into 10-mm2 sections, washed with PBS, pH 7.0, to remove blood, fixed in formalin, and embedded in paraffin. Sections were stained with a rabbit antibody raised to rat fibrin monomer which is reactive to fibrin and fibrinogen (anti–rat fibrin IgG, 50 μg/ml, provided by Dr. Jel Emeis, Gabius Institute, The Netherlands) (10). Sites of primary antibody binding were visualized with a peroxidase-conjugated secondary antibody, goat anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO).

Electron microscopy. Mouse lung tissue was fixed in 2.5% glutaraldehyde and sections stained with uranyl acetate and lead. Transmission electron microscopy was performed using a Jeol 100 CX-2 microscope (Jeol, Ltd., Tokyo, Japan).

Immunoblotting. Lung tissue, harvested as above, was placed in buffer (Tris, 0.05 M, NaCl, 0.15 M, heparin, 500 U/ml, final pH 7.6) on ice and homogenized (Brinkmann Instruments, Inc., Westbury, NY). Plasmin digestion was performed by a modification of the methods of Francis (11). Human plasmin (0.52 U/ml, Sigma Chemical Co.) was added to the tissue homogenate, followed by agitation at 37°C for 6 h. More plasmin (0.32 U/ml) was then added, and samples were agitated for an additional 2 h, then the mixture was centrifuged at 2,300 g for 15 min and the supernatant aspirated. As a positive control, mouse fibrinogen (2.5 mg in 0.25 ml; Sigma Chemical Co.) was clotted with human thrombin (4 U; Sigma Chemical Co.) in tris-buffered saline (1.75 ml) in the presence of calcium chloride (0.013 ml of 2.5 M) for 4 h at room temperature. Clotted fibrinogen was lyophilized, ground into a fine powder with a glass rod, suspended in 1,750 μl tris-buffered saline containing human plasmin (0.32 U/ml) and agitated at 37°C. Additional plasmin (0.32 U/ml) was added after 6 h and samples were agitated for an additional 2 h, after which no visible thrombus was present. As a negative control, unclotted mouse fibrinogen was processed in an identical manner. Samples of plasmin-treated hypoxic and normoxic lung homogenates (220 μg), and plasmin-treated clotted and unclotted fibrinogen (1.7 μg) were boiled in reducing SDS-sample buffer for 5 min, and subjected to SDS-PAGE (10%, reduced). Samples were electrophoretically transferred to nitrocellulose, and blots were reacted with a polyclonal rabbit anti-human antibody prepared to gamma–gamma chain dimers present in cross-linked fibrin (12) followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (Sigma Chemical Co.). Final detection of bands was performed using the enhanced chemiluminescent Western blotting system (Amercham International, Buckinghamshire, England). Optical density of bands was determined by scanning radiograms with a ScanJet IICX (Hewlett-Packard Co., Palo Alto, CA), linked to a Macintosh 8500 computer (Apple Computer, Inc., Cupertino, CA), with subsequent analysis using NIH Image software.

Accumulation of radioiodinated fibrinogen and IgG in the lung. Mouse fibrinogen or mouse nonimmune IgG (Sigma Chemical Co.) were labeled with Na125I (DuPont NEN, Boston, MA) using the Iodo- bead method (Pierce Chemical Co., Rockford, IL). The specific radioactivity of tracers was ~ 106 cpm/ng, and radiolabeled proteins were > 95% precipitable in 10% trichloroacetic acid. Animals received 50–200 ng of either 125I-labeled fibrinogen or 125I-labeled non-immune IgG (2–6 μCi in 0.2 ml saline) via the tail vein. Experiments with hypoxic and normoxic mice, or with hypoxic experimental and hypoxic control mice, were conducted simultaneously using the same batch of labeled protein. At the conclusion of the experiments, mice were treated with heparin, immediately killed, and lungs were harvested, washed, dried, weighed, and assessed for tissue-associated radioactivity. Where indicated, mice were treated with hirudin (13) (0.5 mg/kg per h dissolved in saline) or saline alone delivered subcutaneously via osmotic pumps (Alza Corp., Palo Alto, CA) for 8 h before receiving tail vein injections of 125I-fibrinogen followed by hypoxic exposure. The thrombin time (13) in hirudin-treated animals was determined using a kit purchased from Sigma Chemical Co.

Isolation and labeling of mouse platelets, neutrophils (PMNs), and MPs. To assess deposition of platelets, PMNs, and MPs in hypoxic versus normoxic lung, cell populations were isolated, radiolabeled, and infused into mice as follows below.

Platelets were isolated as described (14). In brief, mouse blood obtained by direct cardiac puncture was anticoagulated with 3.7% sodium citrate and centrifuged at room temperature, first at 300 g for 5 min to obtain platelet-rich plasma, which was then washed three times with saline and centrifuged at 2,000 g for 15 min. Platelets (3 × 108) were resuspended in 1 ml of PBS and incubated under constant agitation with 100 μCi of 111In-oxine (Amersham Mediphysics Corp., Arlington Heights, IL) for 30 min at 37°C. After labeling, platelets were washed three times with PBS and resuspended in saline; each animal received the 111In-labeled platelets by tail vein injection (3–4 μCi in 0.2 ml) at the start of each experiment, with mice exposed to normoxia or hypoxia. At the indicated time points, mice were treated with heparin, killed, lungs were harvested, washed, dried and specific activity determined (expressed as cpm/mg dry tissue weight).

PMNs and MPs were isolated from mouse blood obtained by direct cardiac puncture in anesthetized mice and anticoagulated with 3.7% sodium citrate. To obtain PMNs, citrated blood was diluted 1:1 with NaCl (0.9%) and subjected to gradient centrifugation at 500 g on Ficol-Hypaque (Pharmacia Biotech, Piscataway, NJ) at room temperature for 20 min. After hypotonic lysis of residual erythrocytes (20-s exposure to distilled water and then reconstitution with 1.8% saline), PMNs (> 95% homogeneous cell population) were suspended in HBSS with 5 mg/ml of BSA (HBSS/A) and were labeled with 111In-oxine using a modification of the method of Zimmerman (15). Approximately 12 × 106 cells, suspended in 2 ml HBSS/A, were incubated with 111In-oxine (0.5 μCi/106 cells; Amersham Mediphysics Corp.) at 37°C for 15 min under constant agitation. The suspension was centrifuged at 450 g for 5 min and the pellet washed twice with HBSS/A, with centrifugation at 450 g for 5 min. The washed PMN pellet was resuspended in PBS (5 × 106 cells/ml). Each animal received ~ 8 × 1010 PMNs by tail vein injection at the start of experiments. MPs were isolated by density gradient centrifugation as follows. Citrated mouse blood was diluted 1:1 with NaCl (0.9%) and 2 ml of this diluted blood was added to an equal volume of Histopaque 1077 (Sigma Chemical Co.), centrifuged at 400 g for 30 min. The layer of mononuclear cells was aspirated, washed three times with PBS using centrifugation at 250 g for 10 min. Cell pellets were resuspended in 3 ml RPMI 1640 medium containing 10% FBS (GIBCO, Grand Island, NY) and plated on 35-mm culture dishes (Becton Dickinson Labware, Lincoln Park, NJ) followed by incubation at 37°C for 4 h. After washing twice with PBS, adherent cells were incubated with 111In-oxine (0.5 μCi/106
cells; Amersham Mediphysics) in PBS for 15 min at 37°C, gently scraped, washed twice with PBS using centrifugation at 250 g for 10 min, and resuspended in PBS (1 × 10^6 cells/ml). Each animal received ~ 2 × 10^4 MPs by tail vein injection at the start of experiments. At the indicated time points, mice were treated with heparin, killed, lungs were harvested, and tissue was processed as described for platelets.

Depletion of platelets, PMNs, and MPs. To determine the role of platelets, PMNs and MPs in fibrin formation in hypoxic mouse lung, the effect of antibody-induced depletion of each of these cell types was studied. After depletion of either platelets, PMNs or MPs, the effect on [125]I-fibrin/fibrinogen incorporation was studied by infusing [125]I-fibrinogen as described above. The complement activity of antibody-treated animals was compared with standard complement sera by lysis of antibody-sensitized sheep red blood cells using reagents purchased from Sigma Chemical Co.

Platelet depletion was accomplished by administering by tail vein 0.1 ml of either rabbit anti-murine platelet or control sera (Accurate Chemical and Science Corp., Westbury, NY). Platelet counts 16 h after antiplatelet antisera treatment were ~ 14,000/μL. Treatment with control sera resulted in no change in platelet count.

MP or PMN depletion was accomplished using either rabbit anti-murine MP or antimurine PMN sera (Accurate Chemical and Science Corp.) (16, 17). Animals received daily intraperitoneal injections (0.3 ml) for 3 d. Wright Giemsa–stained peripheral blood smears of anti-MP antibody-treated animals taken 24 h after injection showed < 1% circulating MPs; anti-PMN antibody-treated animals displayed absence of PMNs. In contrast, MPs and PMNs were unaffected in control animals.

Expression of TF, and in vitro and in vivo inhibition of TF activity. TF expression was detected in isolated murine MPs and in hypoxic murine lung by immunostaining, and in lung by Northern blotting. To establish that the anti–rabbit TF IgG (18) used for immunostaining blocked tissue factor functional activity, its ability to prolong the prothrombin time (PT) of mouse plasma was assessed. In vivo experiments were then conducted to assess the impact of the antibody on hypoxic pulmonary deposition of [125]I-fibrin/fibrinogen.

Northern analysis of normoxic and hypoxic mouse lung RNA for TF was performed by first isolating total RNA using the RNA STAT-60 procedure (Tel-Test Inc., Friendswood, TX). RNA was subjected to electrophoresis on 0.8% agarose gels, transferred to nitrocellulose, and incubated with the primary antibody (36°C for 15 min, and centrifuged (500 g for 10 min); the supernatant was aspirated and stored at ~ 20°C and used in subsequent assays. Rabbit brain thromboplastin was purchased from Sigma Chemical Co. 20 μg of each thromboplastin preparation was subjected to SDS-PAGE (10% gel), transferred to nitrocellulose, and incubated with the primary antibody (36 μg/ml) for 12 h at 4°C after blocking with 8% milk protein for 2 h at room temperature. After washing in PBS with 0.1% Tween 20, peroxidase-conjugated anti–goat IgG secondary antibody, (1 μg/ml; Sigma Chemical Co.) was added. Final bands were detected on x-ray film using the enhanced chemiluminescent system (Amersham International).

Immunohistochemistry for TF antigen was performed using the goat IgG against rabbit TF on lung tissue from normoxic or hypoxic animals, with an alkaline phosphatase-conjugated rabbit anti–goat secondary antibody (Sigma Chemical Co.). As a positive control for TF, immunohistochemistry was performed on paraffin-embedded sections of epidermis from normal mice. To determine immunostaining specificity, blocking of goat anti–rabbit TF IgG was accomplished by preincubating the antibody with purified rabbit TF before immunostaining (50 μl of purified rabbit TF [50 μg/ml] incubated overnight at 4°C with 1 ml of anti-TF antibody [9 μg/ml]). To confirm the identity of the cells expressing TF, a dual-labeling procedure was employed (21). In this technique, the section was first immunostained with an antibody against the MP antigen, F4/80 (a rat anti–mouse monoclonal antibody (22) (Caltag Laboratories, So. San Francisco, CA) and developed with an alkaline phosphatase-conjugated anti-rat secondary antibody (Sigma Chemical Co.) and photographed. After decolorization, immunostaining for TF was performed using the goat IgG against rabbit TF with a horseradish peroxidase-conjugated anti–goat secondary antibody (Sigma Chemical Co.), and the section rephotographed. This technique allows side-by-side comparison of the same tissue section.

Murine MPs were isolated from 12 ml of blood as described previously and re suspended in 16 ml of RPMI 1640 medium containing 10% FBS (GIBCO). The cell suspension was incubated for 1 h at 37°C on 4 Permanox chamber slide two-well culture chambers (Nunc Inc., Naperville, IL) and washed three times with PBS to remove nonadherent cells. Serum-free RPMI was then added to the culture chambers and cells were quiescent for 24 h. Cells were then left in the normoxic incubator or placed in a hypoxic incubator (pO2 16 mmHg) for 16 h, washed with HBSS, and fixed with formalin. Cells were stained with anti–rabbit TF IgG, with sites of primary antibody binding visualized with an alkaline phosphatase-conjugated rabbit anti–goat secondary antibody (Sigma Chemical Co.). To identify the adherent cells as MPs, immunostaining for F4/80 antigen was performed using the rat anti–mouse monoclonal antibody (Caltag Laboratories) and a horseradish peroxidase-conjugated secondary antibody (Sigma Chemical Co.).

In vivo inhibition of TF procoagulant activity using the goat anti–rabbit TF IgG was assessed by the prothrombin time assay (PT; Sigma Chemical Co.). A standard clotting curve was constructed as follows: mouse brain thromboplastin was serially diluted with normal saline, mixed with an equal volume of 0.02 M calcium chloride (Dade Division, Baxter Corp., Miami, FL) and added to half the volume of citrated mouse plasma, and the time to thrombus formation was measured. All reagents were reacted at 37°C. A 72-fold protein excess of either goat anti–rabbit TF IgG or goat nonimmune IgG was pre incubated with the diluted mouse thromboplastin for 1 h at 37°C, and the PT was measured. The amount that the clotting time was changed by the addition of anti-TF IgG or nonimmune IgG was converted to percentage of TF activity from the standard curve, with 100% TF activity representing the PT without addition of IgG.

In vivo inhibition of TF using goat anti–rabbit TF IgG was assessed by pretreatment of mice (by tail vein injection) with 150 mg/kg of either goat anti–rabbit TF IgG or goat nonimmune IgG (control), given 2 h before 16 h of hypoxic exposure. Tissue was then harvested and analyzed for [125]I-fibrin/fibrinogen deposition and cross-linked fibrin accumulation, as described.

Statistical analysis. Results are expressed as means ± SEM with SEM for ratios calculated as described by Cochran (23). Statistical analysis was performed using the Student’s two-tailed unpaired t test for comparisons between two groups, using Statview software (Abacus Concepts, Inc., Berkeley, CA). Differences were considered significant if P ≤ 0.05.

Hypoxia and Coagulation

1731
Results

Deposition of fibrin, radioiodinated fibrin/fibrinogen, and platelets in hypoxic pulmonary vasculature. Tissue fibrin deposition induced by hypoxic exposure was first demonstrated by immunohistochemistry using a rabbit antibody raised to rat fibrin monomer (10). Staining performed on freshly isolated lung tissue (with antemortem heparin administration to limit postmortem clotting) demonstrated intravascular fibrin deposition as early as 4 h that became especially evident by 8 h in hypoxic animals (Fig. 1A), but not in normoxic controls (Fig. 1B).

Electron microscopy was performed to confirm the presence of fibrin; platelet-associated fibrin demonstrated the characteristic 22.5-nm strand periodicity (24; Fig. 1, C and D).

Immunoblots of lung tissue extracts were then performed to provide additional confirmation of hypoxia-induced thrombosis. These studies used antibody raised to the gamma-gamma chain dimer present in cross-linked fibrin (12). Extracts of lung

Figure 1. Fibrin deposition in pulmonary vasculature from mice exposed to hypoxia or normoxia. Mice were exposed to hypoxia (A), FiO₂ of ~6%, or maintained in normoxia (B) for 8 h, followed by administration of heparin before killing. Tissue was immunostained with antifibrin antibody. A and B, ×600; (L) vascular lumen; (arrows) vascular endothelium; *red blood cells. Experiments with the same concentration of nonimmune serum demonstrated no staining (data not shown). Electron micrograph of hypoxic (16 h) murine pulmonary vasculature (C) showing endothelium, red blood cells (RBC), platelet clumping (Plt), and platelet-associated fibrin (arrow). Higher magnification (D) demonstrates 22.5-nm periodicity characteristic of fibrin; black bar, 112 nm. C, ×12,450; D, ×44,650.
were digested with plasmin, and the digest applied to reduced SDS-PAGE. As a positive control for fibrin, murine fibrinogen clotted in vitro and digested by plasmin displayed a similarly migrating band to the hypoxic lung digests (Fig. 2). Densitometric analysis comparing the known amount of fibrin loaded in the fibrin lane with that in hypoxia lane reveals that ∼1.2 μg of fibrin are present per mg of hypoxic lung tissue. In contrast, plasmin digests of unclotted fibrinogen or normoxic mouse lung demonstrated no discernible bands (Fig. 2, fibrinogen or normoxia lanes, respectively).

As a more rapid and semiquantitative assay for fibrin deposition in hypoxic lung in vivo, accumulation of 125I-fibrin/fibrinogen was studied. For these experiments, 125I-fibrinogen or 125I-fibrin (control protein) was injected into mice, after which they were randomly separated into normoxic or hypoxic exposure groups for the indicated durations. Accumulation of 125I-IgG was not different between hypoxic and normoxic tissue up to 16 h (Fig. 3), though at longer times (24 h and beyond, data not shown) there was an increase in IgG deposition, consistent with increased vascular permeability on prolonged exposure to oxygen deprivation (25). In contrast, there was a steady rise in 125I-fibrin/fibrinogen in the hypoxic lung versus normoxic controls (Fig. 3; cpm/g in hypoxic/normoxic lung tissue at 1, 4, 8, and 16 h, respectively, were 5.0 × 10^3 ± 6.6 × 10^3; 4.5 × 10^4 ± 3.7 × 10^3; 5.8 × 10^4 ± 6.2 × 10^4; 4.2 × 10^5 ± 1.2 × 10^6; 3.2 × 10^5 ± 2.1 × 10^6; 10^6 ± 2.1 × 10^6; 2.8 × 10^6 ± 2.3 × 10^6; 7.7 × 10^6 ± 7.3 × 10^6, respectively). In addition, 111In-labeled platelets accumulated in hypoxic lung in a time-dependent manner versus normoxic controls (Fig. 4; cpm/g in hypoxic and normoxic lung at 2, 4, 8, and 16 h, respectively, were 2.2 × 10^4 ± 2.5 × 10^4; 1.8 × 10^5 ± 4.8 × 10^5; 2.4 × 10^5 ± 1.2 × 10^6; 1.5 × 10^6 ± 2.0 × 10^6; 1.1 × 10^6 ± 1.1 × 10^6; 7.3 × 10^6 ± 5.5 × 10^6; 1.8 × 10^7 ± 1.1 × 10^8; 3.9 × 10^7 ± 1.7 × 10^8, respectively).

Further evidence confirming that activation of coagulation was responsible for accumulation of 125I-fibrin/fibrinogen and cross-linked fibrin in hypoxic murine lung was derived from studies with the thrombin inhibitor hirudin (13). Mice pretreated with hirudin at a dose which increased thrombin time from 18 to 50 s demonstrated inhibition of hypoxic 125I-fibrin/fibrinogen deposition (Fig. 5 A) and a decrease in the Western blotting signal for fibrin gamma–gamma dimer (Fig. 5 B). To evaluate whether platelets, which provide a major amplification mechanism for activation of the procoagulant pathway, also participate in hypoxia-induced thrombosis, the effect of platelet depletion on hypoxia-induced 125I-fibrin/fibrinogen accumulation was examined. Platelet depletion reduced pulmonary 125I-fibrin/fibrinogen accumulation (Fig. 5 A).

Involvement of PMNs and MPs in hypoxia-induced accumulation of radioiodinated fibrin/fibrinogen in hypoxic lung. To explore potential mechanisms which might initiate hypoxia-induced thrombosis, we examined the roles of other circulating cell types in addition to platelets. For these studies, we used a strategy of depleting certain cell populations and exam-
controls at 8 and 16 h (225 significantly increased in hypoxic lung compared with normoxic 
a representative animal in each treatment group. The figure shows blotting from 
hirudin, anti-TF antibody (gamma–gamma chain dimers was assessed in animals treated with 
expose underlying TF.

we considered the possibility that PMNs drawn into hypoxic 
tissue leukostasis (26), probably through multiple mechanisms, 
Because of previous studies indicating that hypoxia promotes 
ing the impact on hypoxic 

Lawson et al.

Figure 5. The effects of pre-treatment regimens on pulmonary fibrin deposition. (A) The 
effects of hirudin, cell depletion, or TF inhibition on pulmonary deposition of 
125I-fibrin/fibrinogen (125I-Fib) 
after hypoxic exposure (16 h); experimental and control ani-
mal in each group received 
identical amounts of 
125I-fibrinogen. In the hirudin 
xperiments (n = 13), mice re-
w perfused hirudin or saline (control 
group). Either platelets 
(Plt), PMNs, or MPs were de-
pleted (−) with specific anti-
sera, with controls receiving the identical dose of nonimmune sera 
(n = 9, 8, and 8, for Plt, PMN, and MP experiments, respectively). TF was inhibited by goat anti–rabbit TF IgG (Anti-TF IgG) adminis-
tration, with control animals receiving goat nonimmune IgG (Nonim-

mune IgG; n = 11 for TF inhibition experiments). Data are graphed as the percent of control which is the ratio of cpm/g dry tissue in 
treated versus control animals. *P < 0.05 and **P < 0.01 for treated versus control cpm/g. (B) Using identical pretreatment regimens as in the 
125I-fibrin/fibrinogen experiments above, the presence of fibrin 
gamma–gamma chain dimers was assessed in animals treated with 
hirudin, anti-TF antibody (Anti-TF IgG), or depleted of MPs (with 
nonimmune sera serving as a control). The figure shows blotting from 
a representative animal in each treatment group.

ining the impact on hypoxic 125I-fibrin/fibrinogen deposition. Because of previous studies indicating that hypoxia promotes 
tissue leukostasis (26), probably through multiple mechanisms, we considered the possibility that PMNs drawn into hypoxic lung might become activated, damage the endothelium, and 
and expose underlying TF. 111In-labeled PMN accumulation signif-
icantly increased in hypoxic lung compared with normoxic controls at 8 and 16 h (225±30%, 500±50%, respectively; n = 19, P < 0.01 for each time point). Although mice were ren-
dered profoundly neutropenic before hypoxic exposure (plate-
lets and MPs were not reduced on peripheral blood smear), 
hypoxia-induced 125I-fibrin/fibrinogen accumulation in lung re-
mained unaltered (Fig. 5 A).

MPs have the potential to express TF, suggesting that they 
may play a role in thrombotic processes (27, 28). Murine MPs 
labeled with 111In were arrested in hypoxic lung, compared 
with normoxic counterparts (Fig. 4), as early as 2 h after the 
initiation of hypoxic exposure. The possible contribution of 

MPs to 125I-fibrin/fibrinogen deposition and cross-linked fibrin 
formation in hypoxic lung was suggested by studies in which 
MPs were depleted before hypoxic exposure (peripheral blood 
smears confirmed < 1% MPs after antibody administration) 
(16). In MP-depleted animals, hypoxic deposition of 125I-fibrin/
fibrinogen and Western blot fibrin gamma–gamma dimer signal 
were reduced 35 and 65%, respectively (Fig. 5, A and B).

Expression of TF in hypoxic lung and by hypoxic MPs. Because the data suggested that MPs participate in hypoxia-
induced thrombosis, and because MPs are a known source of 
TF (27, 28), we investigated whether hypoxia could trigger TF 
expression in MPs in vitro or in the lung in vivo.

The ability of goat anti–rabbit TF IgG (18) to cross-react 
with murine TF established suitability of using this antibody in 
a murine system. Immunoblotting with mouse brain thrombo-
plastin and rabbit brain thromboplastin preparations (sources of TF) demonstrated comigrating bands of similar molecular 
weights (18, 19, 29; Fig. 6 A). Mouse epidermis, normally high in 
TF, exhibited an intense signal when goat anti–rabbit TF IgG 
was used for immunostaining (Fig. 6 B); the signal was 
markedly diminished by preincubating the antibody with puri-
fied rabbit TF (Fig. 6 C). The ability of goat anti–rabbit TF 
IgG to block TF procoagulant activity was assessed using the 
prothrombin time, a measure of TF-dependent clotting. Prein-
cubation of murine thromboplastin with goat anti–rabbit TF 
IgG resulted in prolongation of the PT equal to a 70% reduc-
tion in TF activity (Fig. 6 D).

Next, expression of TF was studied in lung harvested from 
hypoxic mice. Northern analysis demonstrated a 4.7-fold in-
crease in TF RNA, quantified with NIH Image software, 
whereas β-actin transcripts were unchanged, after 4 h of hy-
poxia (Fig. 7 A). Immunostaining using goat anti–rabbit TF 
IgG showed enhanced antigen expression in hypoxic murine 
lung, compared with normoxic controls (Fig. 7, B and C). In-
creased TF staining in hypoxic lung (Fig. 7 E) occurred in cells 
staining for the MP antigen, F4/80 (Fig. 7 D). In addition, ani-

mals made deficient in circulating monocytes displayed less 
pulmonary TF expression than controls (data not shown). To 
confirm that murine MPs increase expression of TF when de-
prived of oxygen, MPs isolated from murine blood (staining 
for F4/80 antigen; Fig. 7 H) and exposed to hypoxia showed 
enhanced TF immunostaining (Fig. 7 G) compared with nor-
moxic MPs (Fig. 7 F). Having established that goat anti–rabbit 

TF IgG has functional in vitro TF blocking ability (Fig. 7 D), 
we used it to investigate hypoxia-induced thrombosis in vivo, 
as measured by 125I-fibrin/fibrinogen deposition and cross-
linked fibrin formation in hypoxic lung. Mice pretreated 
before hypoxic exposure with goat anti–rabbit TF IgG, but not 
nonimmune IgG, had a 39% suppression of 
125I-fibrin/fibrinogen deposition and cross-linked fibrin 
formation (Fig. 5 A) and a 95% reduction of the fibrin 
gamma–gamma dimer signal by Western blot (Fig. 5 B). Addi-
tional studies demonstrated the half-life of elimination of 
125I-labeled anti-TF IgG in mice to be ~ 53 h, consistent with 
previous measurements of IgG injected into mice (30).

Discussion

In the 1850s, Virchow linked venous thrombosis to hypercoag-
ulability, vascular damage, and stasis (31). In recent years, 
nonpulsatile flow resulting in stasis has been associated with 
rapid intravascular hypoxemia, white blood cell margination, 
and thrombus formation in veins of the lower extremities (4, 5).
These observations, taken together with our previous findings that hypoxia decreased expression of the anticoagulant cofactor thrombomodulin (6), suggested that oxygen deprivation per se might result in a prothrombotic diathesis. In view of the continuing clinical importance of venous thromboembolism, especially in certain high-risk patients (1), we sought to develop an in vivo model allowing investigation of pathophysiologic mechanisms underlying hypoxia-associated thrombosis.

At the outset, we speculated that hypoxia would modulate endothelial properties directly, promoting development of the prothrombotic state. Shatos et al. (32) observed changes in expression of fibrinolytic components. However, in those experiments with ECs, the small increase in plasminogen activator inhibitor-1 and plasminogen activators did not appear to be potent factors promoting fibrin deposition. Similarly, our earlier experiments demonstrating hypoxic suppression of endothelial thrombomodulin at the mRNA, antigen, and activity levels, occurred only after 24 h, whereas fibrin deposition in this study was observed within 4–8 h. Further experiments with hypoxic ECs failed to show induction of TF, though at later times, activation of Factor X (independent of TF) was observed (6). Because ECs exposed to hypoxia express P-selectin...
Lawson et al. (33), IL-8 (26), synthesize platelet-activating factor (PAF) (34), and express intercellular adhesion molecule-1 (ICAM-1) (34) resulting in enhanced adhesivity of hypoxic endothelium for leukocytes and subsequent PMN activation (34), we first investigated whether PMN recruitment might underlie hypoxia-induced thrombosis. Experimental data in our model showed that $^{111}$In-labeled PMNs deposited in hypoxic lung, but that $^{125}$I-fibrin/fibrinogen accumulation was not affected in

![Image](image_url)
neutropenic mice. This suggested that accumulated PMNs were unlikely to mediate early events in the pathogenesis of fibrin deposition associated with oxygen deprivation.

In contrast to PMNs, however, MP recruitment appeared to be involved in the pathogenesis of fibrin formation, as animals deficient in MPs exhibited reduced $^{125}$I-fibrin/fibrinogen and cross-linked fibrin accumulation under hypoxic conditions. Further studies showed that TF expression by recruited MPs was likely to underlie initiation of hypoxia-induced fibrin deposition. These data lead us to propose a scenario in which MPs are recruited into hypoxic lung, become activated, and express TF which promotes fibrin formation. Platelets also accumulate, amplifying the thrombotic process. In support of our concept that MPs contribute to pathologic fibrin formation associated with hypoxia, we have also found that hypoxic MPs also synthesize increased amounts of a key inhibitor of the fibrinolytic pathway, plasminogen activator inhibitor-1 (PAI-1) (35).

Monocyte regulation of coagulation in hypoxia is consistent with previous data that suggest an active role for MPs in other aspects of the physiologic/pathophysiological response to oxygen deprivation, such as elaboration of angiogenic factors (36, 37). Whereas others have shown that TF plays an important role in pulmonary fibrin deposition in response to injury (38), in our model, hypoxia alone was a sufficient stimulus for TF induction. Interference with hypoxic MP recruitment or TF expression in vivo, either by decreasing the number of MPs, or by blocking TF with anti-TF IgG, resulted in decreased thrombosis, as measured by hypoxia-induced $^{125}$I-fibrin/fibrinogen and cross-linked fibrin accumulation. These data support observations demonstrating induction of TF in alveolar macrophages in lung subjected to ischemic preservation (39).

Although it is possible that our experimental method of MP depletion (immunodepletion) may have affected more than one cell type, this was not evident on peripheral smears. In addition, complement activity in the MP- and PMN-depleted animals was normal (data not shown). PMNs, though having an identified role in platelet interaction (40), and accumulating later on in hypoxic lung tissue in our experiments, do not appear to be involved in the initiation of hypoxia-induced thrombosis. The ability of hirudin, platelet or MP depletion, and anti-TF antibody administration to only partially suppress $^{125}$I-fibrin/fibrinogen deposition, but more fully inhibit cross-linked fibrin accumulation (measured by Western blotting for gamma–gamma dimer) suggests that there is high background signal present in the $^{125}$I-fibrin/fibrinogen assay. Distinguishing intravascular from extravascular sites of thrombosis using whole-lung assays ($^{125}$I-fibrin/fibrinogen deposition and Western blotting for gamma–gamma dimer) is complicated by the potentially procoagulant environment of the alveolar space. However, in the current experiments, immunohistology demonstrates that there is intravascular fibrin formation in this model.

One potential experimental limitation involves the need to use living animals in this model of hypoxia-induced thrombosis. As with any in vivo model, it is possible that oxygen deprivation might foster systemic cytokine activation, and enhanced TF expression in circulating MPs as well as extravascular cells. In the same light, MPs themselves could also indirectly induce TF expression elsewhere in the lung through the elaboration of mediators. Our results, therefore, may reflect both local and systemic factors. To examine the effect of whole animal hypoxia on impaired intestinal barrier function (which could increase systemic exposure to endotoxins and complicate local findings of TF production), plasma from mice exposed to 16 h of hypoxia (n = 3) and normoxia (n = 3) was assayed for endotoxin by the Limulus amebocyte lysate method (41) (E-Toxate, Sigma Chemical Co.). In both groups of mice, endotoxin was undetectable, indicating that the duration and degree of hypoxia used in these experiments did not result in endotoxemia within the detection limits of the assay (0.06 EU/ml).

This in vivo model of hypoxia-induced thrombosis might constitute a useful method for evaluating transgenic and knockout mice with alterations in the coagulation system (42–44). Our hypothesis to explain early fibrin formation in settings of oxygen deprivation raises important questions concerning underlying mechanisms. How are MPs recruited into hypoxic loci? By what means does oxygen deprivation increase TF? What other factors in hypoxic and ischemic microenvironments prime the procoagulant pathway and/or suppress natural antithrombotic mechanisms? Answers to these questions will provide critical tests of our hypothesis and provide new insights to delineate hypoxia-inducible mechanisms promoting fibrin formation in a range of ischemic conditions.

Acknowledgments

We thank Dr. O. Chappey for calculating anti-TF IgG disposition parameters, and Dr. Gabriel Godman for helpful advice and suggestions. Dr. Pinsky performed this work during the tenure of a Clinician-Scientist Award from the American Heart Association.

This research was supported by a Foundation for Anesthesia Education and Research Young Investigator Award through a grant from Mallinckrodt Anesthesiology (C.A. Lawson), U.S. Public Health Service grants HL55397, (D.J. Pinsky), HL35246, (W. Kisiel), and HL50629 and HL42507, (D.M. Stern), and by grants from the American Heart Association and the Cystic Fibrosis Foundation (D.J. Pinsky).

References


